1. Academic Validation
  2. Inhibitors of Ketohexokinase: Discovery of Pyrimidinopyrimidines with Specific Substitution that Complements the ATP-Binding Site

Inhibitors of Ketohexokinase: Discovery of Pyrimidinopyrimidines with Specific Substitution that Complements the ATP-Binding Site

  • ACS Med Chem Lett. 2011 Apr 18;2(7):538-43. doi: 10.1021/ml200070g.
Bruce E Maryanoff 1 John C O'Neill 1 David F McComsey 1 Stephen C Yabut 1 Diane K Luci 1 Alfonzo D Jordan Jr 1 John A Masucci 1 William J Jones 1 Marta C Abad 1 Alan C Gibbs 1 Ioanna Petrounia 1
Affiliations

Affiliation

  • 1 Johnson & Johnson Pharmaceutical Research & Development , Spring House, Pennsylvania 19477-0776, United States.
Abstract

Attenuation of fructose metabolism by the inhibition of Ketohexokinase (KHK; fructokinase) should reduce body weight, free fatty acids, and triglycerides, thereby offering a novel approach to treat diabetes and obesity in response to modern diets. We have identified potent, selective inhibitors of human hepatic KHK within a series of pyrimidinopyrimidines (1). For example, 8, 38, and 47 exhibited KHK IC50 values of 12, 7, and 8 nM, respectively, and also showed potent cellular KHK inhibition (IC50 < 500 nM), which relates to their intrinsic potency vs KHK and their ability to penetrate cells. X-ray cocrystal structures of KHK complexes of 3, 8, and 47 revealed the important interactions within the enzyme's adenosine 5'-triphosphate (ATP)-binding pocket.

Keywords

Kinase; crystal structure; diabetes; fructose metabolism; obesity.

Figures
Products